ValiRx Enters Evaluation Agreement with McGill University and IRICoR
Why we think this is good
The agreement with McGill University and IRICoR represents a positive development for ValiRx, as it provides the company with the opportunity to evaluate and potentially license a promising RNA Helicase inhibitor asset. The structure of the agreement, which includes the potential for ValiRx to provide seed funding and obtain an equity stake in the commercialization vehicle, suggests a collaborative and mutually beneficial arrangement. While some financial details are not disclosed, the involvement of reputable academic and research institutions, as well as the potential for new market opportunities, are encouraging signs.
Key Points
- ValiRx, McGill University, and IRICoR have entered a nine-month Evaluation and Material Transfer Agreement
- The agreement focuses on establishing target engagement and potency of a second-generation, orally available, RNA Helicase inhibitor
- ValiRx has an option to license the Evaluation Results into a new Canadian subsidiary company (NewCo) for a pre-agreed equity holding
- ValiRx (and potentially other investors) may provide up to £2 million of seed funding to NewCo for further development and commercialization
- Alternative scenarios are outlined if ValiRx chooses not to proceed with the license
Summary
ValiRx has entered into a nine-month Evaluation and Material Transfer Agreement with McGill University and IRICoR, a Canadian non-profit organization, to establish target engagement and potency of a second-generation, orally available, RNA Helicase inhibitor. The agreement provides ValiRx with an option to license the Evaluation Results into a new Canadian subsidiary company (NewCo) for a pre-agreed equity holding. ValiRx (and potentially other investors) may provide up to £2 million of seed funding to NewCo, which would be used to support the further development and commercialization of the asset. The agreement also outlines alternative scenarios if ValiRx chooses not to proceed with the license.